PR1 leukemia peptide vaccine

Phase 3Vaccine

PR1 leukemia peptide vaccine is one of 74 biologic programs targeting Myelodysplastic Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromePhase 1/Phase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 3

50 2

Peony

Takeda

Phase 3

6 3

Empaveli

Gilead

Phase 3

4 4

Zarnestra

KKura Oncology, Inc.

Phase 3

9 5

Salvage Chemotherapy

Daiichi Sankyo

Phase 3

1 6

PR1 leukemia peptide vaccine

TThe Vaccine Company

Phase 3

1 7

Grafalon

FFundación Canaria de Investigación Sanitaria

Phase 3

1 8

Leukine

Sanofi

Preclinical

7 9

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

8 10

Antibiotic

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00004918·69 enrolled

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Unknown status·TThe Vaccine Company·Phase 2·NCT00513578·30 enrolled

Acute Myeloid Leukemia1 trial

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

Unknown status·TThe Vaccine Company·Phase 3·NCT00454168·244 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PR1 leukemia peptide vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PR1 leukemia peptide vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PR1 leukemia peptide vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Vaccine Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: TThe Vaccine Company

PR1 leukemia peptide vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News